The U.S. Food and Drug Administration has approved expanded access to daraxonrasib, a breakthrough targeted therapy for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). Known as the “king of cancers” for its devastating mortality rate, pancreatic cancer has long resisted effective treatment, making this approval a significant milestone for patients and oncologists alike.

The Drug

Daraxonrasib is a targeted therapy designed for pancreatic cancer patients carrying specific genetic mutations. The New York Times reported that the drug has demonstrated encouraging efficacy in clinical trials, showing the ability to significantly extend patient survival.

Expanded Access Program

The FDA’s Expanded Access program allows experimental drugs to be used outside of clinical trials for patients with serious or life-threatening conditions who have no comparable treatment alternatives. USA Today reported that this decision enables a broader pool of pancreatic cancer patients to receive daraxonrasib ahead of full regulatory approval.

Targeted Oncology noted that the approval specifically applies to previously treated metastatic PDAC patients — a population with extremely limited treatment options after first-line therapies fail.

The Pancreatic Cancer Challenge

Pancreatic cancer has long been one of oncology’s greatest challenges. Its early symptoms are subtle, diagnoses typically occur at advanced stages, and the disease responds poorly to conventional chemotherapy. The five-year survival rate remains below 10%, the lowest among all major cancers.

Patient Impact

According to WKOW, doctors at UW Health expressed excitement about the breakthrough developments in pancreatic cancer treatment. The expanded access approval for daraxonrasib means more patients will have a new treatment avenue after standard therapies have failed.

Future Outlook

Daraxonrasib remains in further clinical trials to collect the data needed for full FDA approval. If subsequent trial results confirm its safety and efficacy, the drug could become a standard component of pancreatic cancer treatment protocols.

Analysts note that this approval also reflects the FDA’s continued flexible approach to accelerating innovative drug reviews, particularly for fatal diseases lacking effective treatment options.

Source: New York Times | USA Today | Targeted Oncology

According to The New York Times and Reuters, the US Food and Drug Administration (FDA) has approved expanded access to daraxonrasib, an innovative pancreatic cancer drug, offering new hope for patients facing one of the deadliest forms of cancer.

Pancreatic cancer is one of the most aggressive and lethal cancers, with a five-year survival rate of approximately 12%. Because early symptoms are often unnoticeable, most patients are diagnosed at advanced stages when treatment options are extremely limited. Daraxonrasib, developed by Revolution Medicines, is a targeted drug aimed at KRAS gene mutations—one of the most common oncogenic mutations in pancreatic cancer.

Under the FDA’s expanded access program (also known as “compassionate use”), eligible pancreatic cancer patients can receive the treatment before the drug is formally approved for market. This policy applies to patients who have no other available treatment options and are not eligible for clinical trials.

Reuters reported that the drug has shown encouraging efficacy data in early clinical trials. Among treated patients, some demonstrated significant tumor shrinkage, and the drug was well-tolerated. Revolution Medicines plans to submit a New Drug Application (NDA) to the FDA later this year, seeking formal approval.

The New York Times analysis noted that the field of pancreatic cancer treatment has long lacked major breakthroughs, and daraxonrasib represents a significant advance. KRAS mutations were once considered “undruggable,” but in recent years, advances in drug development technology have led to remarkable progress in KRAS-targeted therapeutic strategies.

According to American Cancer Society data, pancreatic cancer causes approximately 50,000 deaths annually in the United States, making it one of the deadliest cancers globally. The expanded access approval means some patients can obtain this potentially life-extending treatment sooner.

An oncologist at UW Health described the development as “exciting” but also cautioned patients and doctors to maintain realistic expectations, as long-term efficacy and safety data still require further validation.

Sources: The New York Times, Reuters, USA Today

Drug Background

Daraxonrasib is a selective inhibitor targeting the KRAS G12D mutation, developed by Revolution Medicines. KRAS gene mutations are one of the most common drivers of pancreatic cancer, accounting for approximately 35% to 40% of cases. For decades, KRAS mutations were considered “undruggable,” but recent technological advances have made it possible to selectively target specific KRAS mutations.

Clinical Trial Data

In early-stage clinical trials, daraxonrasib has demonstrated encouraging efficacy data. Some patients experienced significant tumor shrinkage, with disease control rates surpassing existing standard-of-care treatments. Perhaps most importantly, the drug has shown a favorable tolerability profile, with manageable side effects.

According to The New York Times, former U.S. Senator Ben Sasse is among the beneficiaries of the drug. After being diagnosed with pancreatic cancer, Sasse participated in the clinical trial and has seen his condition effectively controlled.

Expanded Access Program

The FDA’s approval of the Expanded Access Program, also known as “compassionate use,” allows patients with serious or life-threatening conditions to access investigational drugs before they receive formal approval.

This mechanism is particularly important for patients who are ineligible for ongoing clinical trials and have no other effective treatment options. Pancreatic cancer, often called the “king of cancers,” has a five-year survival rate of only about 12%, making it one of the cancer types with the most urgent need for new therapies.

Industry Significance

Analysts note that daraxonrasib’s progress is significant not only for pancreatic cancer patients but also opens new possibilities for treating other KRAS-mutated solid tumors, including colorectal cancer and non-small cell lung cancer.

Revolution Medicines’ shares rose following the announcement, reflecting market optimism about the drug’s commercial prospects. If daraxonrasib ultimately receives full FDA approval, it would represent a major milestone in pancreatic cancer treatment.

Next Steps

Revolution Medicines plans to continue advancing daraxonrasib through Phase III clinical trials to gather more comprehensive efficacy and safety data in support of full marketing approval. The company expects to report interim results from the pivotal trial within the next year.

Source: The New York Times, Reuters

The U.S. Food and Drug Administration (FDA) approved expanded early access for the experimental pancreatic cancer drug daraxonrasib on May 1, 2026. This decision brings new hope for late-stage pancreatic ductal adenocarcinoma (PDAC) patients and has sparked enthusiastic discussion in the medical community about the broad potential of targeted therapy in oncology.

Drug Background

Daraxonrasib is an experimental drug targeting the KRAS G12D mutation. KRAS gene mutations are extremely common in pancreatic cancer, with approximately 30-40% of PDAC patients carrying this mutation. For decades, KRAS was considered an “undruggable” target until recent breakthroughs in targeted therapy technology made substantive progress possible.

According to the New York Times, the drug has shown encouraging efficacy in early clinical trials — some late-stage pancreatic cancer patients experienced significant tumor shrinkage, with a few cases achieving complete remission. This result represents a milestone in pancreatic cancer treatment, as the disease has long been called the “king of cancers” with a five-year survival rate of less than 13%.

Expanded Access Program

The FDA’s approval is for an “Expanded Access” protocol, also known as “Compassionate Use.” This mechanism allows patients with serious or life-threatening diseases to access experimental drugs before they receive full regulatory approval.

According to the Washington Post, CBS News reported that former Senator Ben Sasse is one of the beneficiaries of this drug, sharing his treatment experience publicly. This high-profile political figure’s involvement has further elevated public awareness of the drug.

Professional medical journals including OncLive and Targeted Oncology have both covered this development in detail, noting that the approval of the expanded access protocol means the drug has received the FDA’s basic safety endorsement, paving the way for large-scale clinical trials and eventual market approval.

The Pancreatic Cancer Treatment Challenge

Pancreatic cancer is one of the deadliest cancers globally, characterized by difficulties in early diagnosis, poor response to traditional chemotherapy, and low surgical resection rates. According to the American Cancer Society, approximately 66,000 people in the United States are expected to be diagnosed with pancreatic cancer in 2026, with about 51,000 dying from the disease.

Mayo Clinic’s recently developed REDMOD AI system has demonstrated the ability to identify pancreatic cancer signatures from CT scans an average of 16 months before diagnosis (as reported in today’s AI & Tech section), while daraxonrasib’s progress represents an important breakthrough on the treatment side. The combination of AI-assisted diagnosis and targeted therapy may be reshaping the entire pancreatic cancer care ecosystem.

Looking Ahead

Analysts note that if daraxonrasib can confirm its efficacy in large-scale Phase III clinical trials, it would represent a major breakthrough in pancreatic cancer targeted therapy — the first in decades. Currently, multiple pharmaceutical companies are competing in this space, including other targeted drugs aimed at KRAS G12C mutations.

The expanded access approval means eligible patients can access treatment before the drug’s formal market approval, but it also requires doctors and patients to fully understand the drug’s experimental nature and potential risks.

Source: New York Times | USA Today | Washington Post